The PI3K/AKT/mTOR pathway integrates growth-factor, nutrient and energy signals to regulate cell survival, growth and metabolism. Cancer can increase pathway output at different nodes: PIK3CA hotspot mutations can activate the p110α catalytic subunit, PTEN loss can reduce removal of the lipid signal PIP3, AKT1 E17K can change membrane recruitment, and receptor or RAS alterations can provide upstream input. These events converge partly, but they are not biologically or clinically interchangeable.
RTK activation recruits the PI3Kα heterodimer (p110α–p85) to the membrane, where p110α phosphorylates PIP2→PIP3. PTEN opposes this reaction by dephosphorylating PIP3→PIP2. PIP3 recruits AKT via its PH domain; PDK1 phosphorylates AKT Thr308 and mTORC2 phosphorylates Ser473 for full AKT activation. AKT then phosphorylates >100 substrates — including TSC2 (activating mTORC1), MDM2 (degrading p53), BAD (blocking apoptosis), and GSK3β (stabilising MYC) — creating a central proliferative and survival nexus.
RTK activation recruits the PI3Kα heterodimer (p110α–p85) to the membrane, where p110α phosphorylates PIP2→PIP3. PTEN opposes this reaction by dephosphorylating PIP3→PIP2. PIP3 recruits AKT via its PH domain; PDK1 phosphorylates AKT Thr308 and mTORC2 phosphorylates Ser473 for full AKT activation. AKT then phosphorylates >100 substrates — including TSC2 (activating mTORC1), MDM2 (degrading p53), BAD (blocking apoptosis), and GSK3β (stabilising MYC) — creating a central proliferative and survival nexus.
PI3K / AKT / mTOR Pathway
AKT-mediated TSC2 inactivation allows RHEB-GTP to activate mTORC1 at the lysosomal surface. mTORC1 phosphorylates S6K1 (Thr389) and 4EBP1 (multiple sites), driving ribosome biogenesis and cap-dependent translation of growth-promoting mRNAs.
S6K1 activated by mTORC1 phosphorylates IRS-1 at inhibitory serine residues, reducing insulin receptor→PI3K signal. This negative feedback limits pathway amplitude but paradoxically activates AKT when mTORC1 is blocked by rapamycin/everolimus — the mechanistic basis for compensatory AKT activation on mTOR inhibitors.
PIK3CA mutations occur in ~30% of HR+ breast cancers and are the most common actionable oncogenic alteration in this disease. PTEN loss affects ~30% of glioblastomas and prostate cancers. The pathway drives cancer through four core mechanisms: AKT-mediated apoptotic resistance (BAD phosphorylation), mTORC1-driven protein synthesis and proliferation, MDM2-mediated p53 suppression, and FOXO3a inhibition preventing pro-apoptotic gene expression.
Alpelisib (PI3Kα inhibitor) + fulvestrant is approved for PIK3CA-mutant HR+/HER2− breast cancer. Capivasertib (pan-AKT inhibitor) + fulvestrant is approved for AKT1/PIK3CA/PTEN-altered HR+ breast cancer. Everolimus (mTORC1 inhibitor) is approved for RCC, breast cancer, and pancreatic NETs but causes paradoxical AKT activation via IRS-1 feedback relief. Dual PI3K/mTOR inhibitors (gedatolisib) aim to block both arms simultaneously.
Why does mTOR inhibition with everolimus activate AKT paradoxically?
mTORC1 → S6K1 → IRS-1 creates a negative feedback loop: S6K1 phosphorylates IRS-1 at inhibitory serines, reducing PI3K recruitment to the insulin receptor. When everolimus blocks mTORC1/S6K1, this feedback is relieved, allowing stronger PI3K→AKT signalling. The result is AKT Thr308 phosphorylation and FOXO3a activation — potentially opposing the antiproliferative effect of mTOR inhibition.
What distinguishes alpelisib from pan-PI3K inhibitors?
Alpelisib (BYL719) selectively inhibits PI3Kα (p110α), the isoform encoded by PIK3CA. Pan-PI3K inhibitors that also block PI3Kδ (enriched in lymphocytes) cause dose-limiting immune suppression and colitis. Alpelisib's PI3Kα selectivity reduces immunological toxicity while targeting the specific isoform mutated in breast cancer — the basis for its superior therapeutic index in PIK3CA-mutant disease.
Compare PIK3CA hotspot mutations, PTEN loss and AKT1 E17K: where each acts, what assays detect and why the biomarkers are not interchangeable.
A complete guide to the PI3K/AKT/mTOR signalling axis — the most frequently altered pathway in human cancer — including PIK3CA mutations, PTEN loss, and approved inhibitors.
Understand how tumor suppressor genes — including TP53, BRCA1, PTEN, and RB1 — act as the genome's brakes, and what happens when they are lost in cancer.
Understand sensitising EGFR mutations in NSCLC, how molecular testing is interpreted, and how T790M, C797S, MET amplification and other resistance mechanisms differ.
How HER2 gene amplification drives constitutive receptor signalling, how trastuzumab and antibody-drug conjugates exploit HER2 overexpression, and emerging HER2-low treatment strategies.
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
EGFR–KRAS–BRAF–MEK–ERK Signalling Pathway in Cancer
The EGFR signalling pathway converts extracellular EGF binding into intracellular proliferative and survival signals via…
Tumor Angiogenesis
As solid tumours enlarge, diffusion limits create regions of hypoxia and nutrient stress. Many tumours respond by increa…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Homologous Recombination Repair
Homologous recombination (HR) repairs DNA double-strand breaks primarily in S/G2, when a sister chromatid is available a…
RAS/MAPK Signalling Pathway
The RAS/RAF/MEK/ERK (MAPK) cascade is one of the most ancient and conserved proliferative signalling pathways in eukaryo…